Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 17/20 | 0.59 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639976 | 0.80 | DHODH (0.50) | DHODHTACR3KDM4EHPGDHSD17B10 | |
| SCHEMBL23458441 | 0.75 | POLB (0.58) | DHODHKDM4EHPGD | |
| SCHEMBL17211724 | 0.75 | CYP2D6 (0.56) | DHODHKDM4EHPGDHSD17B10 | |
| SCHEMBL21905205 | 0.74 | DHODH (1.00) | DHODH | |
| SCHEMBL19520848 | 0.71 | MEN1 (0.73) | DHODHTACR3KDM4EHPGDHSD17B10 | |
| SCHEMBL27583672 | 0.70 | KDM4E (0.44) | DHODHKDM4EHPGDHSD17B10 | |
| SCHEMBL29893885 | 0.67 | DHODH (0.44) | DHODHKDM4E | |
| SCHEMBL10212018 | 0.66 | DHODH (0.78) | DHODH | |
| SCHEMBL21974417 | 0.66 | DHODH (0.97) | DHODH | |
| SCHEMBL8312271 | 0.66 | MEN1 (0.53) | DHODHTACR3KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | DHODH 1020/4885TACR3 4052/4885KDM4E 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.